Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma

2018-03-29 10:42:10

Based on findings from the Phase 3 ECHELON-1 trial, brentuximab vedotin (Adcetris) has been approved by the FDA for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.


  • Save
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply